North America Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User

The North America deep brain simulation market is expected to grow from US$ 282.86 million in 2022 to US$ 549.78 million by 2030. It is estimated to grow at a CAGR of 8.7% from 2022 to 2030.

Rising Prevalence of Neurological Disorders Drive North America Deep Brain Simulation Market

The geriatric population is susceptible to neurological diseases. Neuropathy, Parkinson's disease, Alzheimer's disease, and dystonia are among the most common neurological disorders affecting older people. According to the National Institutes of Health (NIH), 8.5% of the world's population (i.e., around 617 million people) are 65 and above. Countries such as the US and Canada have high prevalence rates of movement disorders and psychiatric disorders associated with growing geriatric populations. According to the Parkinson's Foundation, Parkinson's symptoms are common at an average age of 60. The Canadian Psychological Association states that about 2% of the population suffers from obsessive-compulsive disorder (OCD). According to the World Health Organization (WHO), neurological diseases contribute 6.3% to the global disease burden and are one of the leading causes of death across the world. In addition, 13.2% of deaths in developed countries and 16.8% in low- and middle-income countries are reported due to neurological diseases. High mortality and disease burden necessitate the clinical urgency for integrating long-term solutions such as deep brain stimulators (DBS). Therefore, growing awareness regarding the burden of neurological disorders, the growing geriatric population, and the increasing prevalence of neurological diseases propel the demand for deep brain stimulators as a therapy.

North America Deep Brain Simulation Market Overview

The rising prevalence of neurological diseases such as Parkinson's disease (PD), increasing awareness about neurological disorders, positive research results, and growing investments in developing transcranial stimulators are among the main factors driving the overall deep brain stimulation market growth in the US. Deep brain stimulation (DBS) devices have been observed to be effective in controlling the tremors associated with Parkinson's disease. Low dopamine levels and other genetic factors are among the main causes of Parkinson's disease. According to a study titled “2022 Alzheimer's disease facts and figures” published in the Alzheimer's Association, nearly 6.5 million Americans aged 65 and above were found to have Alzheimer's disease in 2022, and that number is projected to rise to 13.8 million by 2060. Technological advancements and new product launches drive the growth of the US deep brain stimulation market. In January 2020, Abbott's Infinity DBS System received US Food and Drug Administration (FDA) approval for treating Parkinson's disease. This system allows for the targeted treatment of a specific area of the brain, called the inner globus pallidus (GPi), which is associated with the symptoms of Parkinson's disease. The US FDA approved the Verses deep brain stimulation device system for treating Parkinson's disease in December 2017 for use by Boston Scientific Corporation. According to the Parkinson's Foundation, around 1 million people in the US are suffering from Parkinson's disease, which is expected to increase to 1.2 million by 2030. Therefore, the increasing prevalence of neurological diseases and technological advancements fuel the North America deep brain simulation market growth in the US.

North America Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Million)

North America Deep Brain Simulation Market Segmentation

The North America deep brain simulation market is segmented into product, application, end user, and country.

Based on product, the North America deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the North America deep brain simulation market.

Based on application, the North America deep brain simulation market is segmented into Parkinson’s disease, tremor, dystonia, epilepsy, Alzheimer’s disease, and others. In 2022, the Parkinson’s disease segment registered the largest share in the North America deep brain simulation market.

Based on end user, the North America deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the North America deep brain simulation market.

Based on country, the North America deep brain simulation market is segmented into the US, Canada, Mexico. In 2022, the US registered the largest share in the North America deep brain simulation market.

Abbott Laboratories, Boston Scientific Corp, Medtronic Plc, and Newronika SpA are some of the leading companies operating in the North America deep brain simulation market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America deep brain simulation market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the North America deep brain simulation market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the deep brain simulation market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution